• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Dermatology

Initial primary invasive or in situ melanoma increases risk of subsequent invasive melanoma

byAdam WhittingtonandAngela Wang
March 23, 2014
in Dermatology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD 

1. Development of subsequent primary invasive melanoma following a first invasive or in situ lesion was significantly increased when compared to the age- and sex-matched general population. 

2. Relative risk of subsequent primary invasive melanoma (SPIM) was greatest at the body site of the original invasive lesion, particularly the head. 

Evidence Rating Level: 2 (Good) 

Study Rundown: The increased risk of SPIM has been correlated to both previous diagnosis of initial primary in situ melanoma and to body region of initial invasive melanoma.  However, relative risks by body site have not been previously identified.  Therefore, these authors examined whether body region, sex, age group, and time since diagnosis influenced the likelihood of a SPIM.  The body site of first primary invasive melanoma had no significance on overall relative risk of SPIM, but an initial in situ melanoma on all body regions except the head correlated with higher relative risk of developing SPIM.  The body site with the greatest risk of SPIM was the region of the original invasive lesion for all subgroups.  Additionally, females with a first primary invasive melanoma on the head were more likely to acquire a SPIM compared to males, and the highest risk of developing SPIM in both sexes was within the first year of initial diagnosis.  Strengths of this study include its large population size and participant diversity within the Queensland area.  However, the replacement of a control population by standardized incident ratio calculations may be considered a weakness.

Click to read the study in JAMA Dermatology

Relevant Reading: Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin

RELATED REPORTS

#VisualAbstract: Tumor-infiltrating lymphocyte therapy compared to ipilimumab in advanced melanoma

#VisualAbstract: Second-line immunosuppression associated with worse outcomes for immune-related adverse events in melanoma

#VisualAbstract: Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma

In-Depth [retrospective cohort]: This study reviewed 39,668 eligible cases of first primary invasive melanoma and 22,845 cases of first primary in situ melanoma between 1982 and 2005 in Queensland, Australia.  Among those, a total of 5,358 patients were diagnosed with SPIM and included in the study cohort.  Standardized incidence ratios (SIRs) were used to measure relative risk and the significance of differences between SIRs was calculated using negative binomial regression.  Results indicated that development of SPIM was 5.4 times more likely (SIR, 5.42; 95% CI, 5.23-5.61) in people with first primary invasive melanoma and 4.6 times more likely (SIR, 4.59; 95% CI, 4.37-4.82) for those with a first in situ primary melanoma than the general population.  For all subgroups, SPIM development was most significant at the site of the original invasive or in situ melanoma, particularly for females with first primary invasive melanoma on the head (SIR, 13.32; 95% CI, 10.28-16.98).  Overall, though, the body region of the first primary invasive melanoma had no effect on the relative risk of SPIM development in the study cohort (P =0.27).

More from this author: Video-based behavioral intervention benefits clinical skin examinations, Biofilm-producing staphylococci occlude eccrine sweat ducts in atopic dermatitis 

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: melanoma
Previous Post

Cesarean in the second stage associated with endometritis

Next Post

Child activity levels correlate with mothers’ activity levels

RelatedReports

#VisualAbstract: Smartphone dispatch of volunteer responders may not increase bystander use of automated external defibrillator in out-of-hospital cardiac arrest
StudyGraphics

#VisualAbstract: Tumor-infiltrating lymphocyte therapy compared to ipilimumab in advanced melanoma

December 22, 2022
#VisualAbstract: Second-line immunosuppression associated with worse outcomes for immune-related adverse events in melanoma
StudyGraphics

#VisualAbstract: Second-line immunosuppression associated with worse outcomes for immune-related adverse events in melanoma

November 17, 2022
#VisualAbstract: Pembrolizumab provides survival benefit in PD-L1 positive advanced head and neck cancer
StudyGraphics

#VisualAbstract: Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma

October 20, 2022
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: World Mental Health Day, Beneath the Band-aid, Trouble in Uganda and Carbon Monoxide Leak Sickens Dozens!

October 18, 2022
Next Post
ADHD stimulant treatment associated with changes in BMI trajectory

Child activity levels correlate with mothers’ activity levels

Avoidable hospitalizations for ESRD increase after transfer to adult care

Low circulating cholesterol in neonates linked with pyloric stenosis

2 Minute Medicine Rewind March 18-24, 2014

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
  • Empagliflozin use is associated with slower progression of chronic kidney disease
  • Diagnostic tool may help identify cerebral palsy regardless of encephalopathy features
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options